Produktbild: Advancements in Personalized Cellular Immunotherapy
Neu

Advancements in Personalized Cellular Immunotherapy A Comprehensive Guide to Cancer Treatment

183,99 €

inkl. gesetzl. MwSt., Versandkostenfrei


Beschreibung

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

01.08.2026

Herausgeber

Singh Arun Kumar + weitere

Verlag

Elsevier

Seitenzahl

438

Maße (L/B)

23,5/19,1 cm

Gewicht

450 g

Sprache

Englisch

ISBN

978-0-443-27731-3

Beschreibung

Portrait

Arun Kumar Singh is an Assistant Professor in the Department of Pharmacy at University School of Pharmaceutical Sciences, Rayat Bahra University V.P.O. Sahauran, India. He completed his M.Pharm in Pharmaceutics from Galgotias University, Greater Noida. His research interests include nano-formulation, blockchain, IoT, machine learning, artificial intelligence, big data analytics, cancer biology, and neuroscience. He has contributed to academic books and book chapters and has published review articles in the areas of pharmaceutical sciences and healthcare technology. His work focuses on interdisciplinary approaches integrating pharmaceutical research with emerging digital and computational technologies.

Dr. Murali Yallapu is a tenured Associate Professor at the University of Texas Rio Grande Valley's School of Medicine, specializing in Immunology, Microbiology, and Oncology and a member of the South Texas Center of Excellence in Cancer Research. Dr. Yallapu received the "Prof. A. Kameswara Rao's Gold Medal-1999" and completed postdoctoral training in materials science, drug delivery, nanomedicine, and cancer biology at institutions including the Cleveland Clinic and the University of Nebraska Medical Center. Before joining UTRGV, he was an Assistant Professor at the University of Tennessee Health Science Center. Dr. Yallapu serves on editorial boards for various journals related to drug delivery, nanotechnology, and cancer, and is an ad-hoc reviewer for the NIH and other funding agencies. He has published over 190 peer-reviewed articles and reviews. His primary research focuses on developing nanomaterials for enhanced therapeutic potential and cancer immunotherapy.

Dr.Ciniraj is presently working as an Associate Professor at Medical College Thiruvananthapuram, Kerala, India, one of the largest multispecialty tertiary care hospitals in southern India. He undertakes teaching courses in oncology for undergraduate and postgraduate students. As a permanent faculty member appointed by the government of Kerala State, he is actively involved in patient care, curriculum development, teaching and evaluation, and clinical research. He actively participates in national and international conferences and institutional research methodology workshops. Currently, he undertakes research projects in clinical oncology at multiple government institutions as primary investigator. He also works as a guide to postgraduate thesis and assists them in their research work. He has a deep interest in oncology research and has published a few original research articles in clinical oncology, which are indexed in Scopus and PubMed. He has reviewed over 100 medical articles for leading publishers, including Elsevier, Springer, and British Medical Journal

Dr. Pranav Kumar Prabhakar is currently working as a Professor and Head at Department of Biotechnology, School of Engineering and Technology, Nagaland University, Meriema, Kohima, Nagaland, India. He is among the World’s Top 2% Scientists (list published by Stanford University, USA, 2021, 2022, 2023, 2024, and 2025). He completed his PhD in Biotechnology from IIT Madras. His research focuses on elucidating molecular mechanisms and strategies for oral insulin delivery and mimicking signaling pathways in metabolic disorders (diabetes) using natural products. Dr. Pranav is a member of the Royal Society of Chemistry and the Asia-Pacific Chemical, Biological & Environmental Engineering Society. He serves as an editorial board member and reviewer for many reputed national and international journals. His honors include a travel grant from IIT Madras and the Council for Scientific and Industrial Research (CSIR) to attend ATTD 2009 in Greece, approved by the Department of Science and Technology (DST). He has published over 160+ research articles, authored/edited 24 books, and 48 book chapters, and delivered 9 oral and poster presentations at scientific meetings.

Produktdetails

Einband

Taschenbuch

Erscheinungsdatum

01.08.2026

Herausgeber

Verlag

Elsevier

Seitenzahl

438

Maße (L/B)

23,5/19,1 cm

Gewicht

450 g

Sprache

Englisch

ISBN

978-0-443-27731-3

Herstelleradresse

Libri GmbH
Europaallee 1
36244 Bad Hersfeld
DE

Email: GPSR Kontakt

Ein neues Kapitel für Ihre Bücher

Ein neues Kapitel für Ihre Bücher

Schenken Sie Ihren alten Schätzen ein zweites Leben und erhalten dafür eine Thalia Geschenkkarte.

Jetzt verkaufen
Jetzt verkaufen

Noch keine Bewertungen vorhanden

Verfassen Sie die erste Bewertung zu diesem Artikel

Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.

Kundinnen und Kunden meinen

Bewertungen (0)

Die Leseprobe wird geladen.
  • Produktbild: Advancements in Personalized Cellular Immunotherapy
  • 1. Introduction to Personalized Cellular Immunotherapy
    2. Understanding the therapeutic significance of tumor-infiltrating immune cells and their characteristics: a historical overview of cancer immunotherapy
    3. A groundbreaking development in cancer treatment: chimeric antigen receptor CART-cell therapy
    4. Recent Progress in CAR-T Cell Therapy for B Cell Cancers with Resistant Tissues
    5. Targeting the tumor vasculature using mesenchymal stem cells in cancer therapy: new perspectives
    6. The use of oncolytic viruses delivered by mesenchymal stromal cells in immunotherapy for the treatment of metastatic tumors
    7. Cancer Treatment Advancements in the Era of Immune Checkpoint Inhibitors via Cellular Immunotherapies
    8. The future of cancer immunotherapy: combining gene and cellular approaches
    9. Platelet Shielding of Cancer Cells: Implications for Immunotherapy Strategies
    10. Cancer Cell-Platelet Interactions: Harnessing Therapeutic Opportunities in Cancer Treatment
    11. Myeloid-Derived Suppressor Cells: A Promising Target for Anticancer Immunotherapy
    12. Utilizing Nanomedicines to Modulate Myeloid-Derived Suppressor Cells: Enhancing Cancer Immunotherapy
    13. Unlocking the Potential of Macrophages: Advancements in Cellular Immunotherapy
    14. Combination therapy: a new strategy to manage cancer
    15. Future perspective of cellular immunotherapy in cancer treatment